Trusted Resources: News & Meetings
Latest announcements and gatherings
Viridian Announces Positive Data From Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients With Thyroid Eye Disease (TED)
Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced positive topline clinical data from the first two cohorts in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune system attacks the tissues around and behind the eyes causing inflammation, swelling, and damage that develops into debilitating signs and symptoms including double vision, bulging eyes, and ocular pain.
“These additional Phase 1/2 clinical data continue to support the potential for VRDN-001 to be a new treatment option for patients suffering from TED,” said Raymond Douglas, M.D., Ph.D., director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center and an investigator on the VRDN-001 trial.
myBinderRelated Content
-
Yale New Haven Children’s Hospital – Pediatric Thyroid CenterThe Pediatric Thyroid Center at Yale New...
-
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
-
Hyperthyroidism and Graves’ DiseaseWhat is the Thyroid? The thyroid is a s...
-
2018 European Thyroid Association Guideline for the Management of Graves’ HyperthyroidismGraves' disease (GD) is a systemic autoi...
-
Treatment of Graves’ Disease – An OverviewHyperthyroidism may be defined as the ex...
-
Thyroidectomy as Primary Treatment Optimizes Body Mass Index in Patients With HyperthyroidismObjective: The purpose of this study wa...
-
Children’s Hospital Los Angeles Thyroid ClinicThe Division of Endocrinology, Diabetes ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google